REFERENCES
1. World Health Organization. Clinical management of COVID-19: interim
guidance, 27 May 2020 (No. WHO/2019-nCoV/clinical/2020.5). 2020. World
Health Organization.
2. Chen J (2020) Pathogenicity and transmissibility of 2019-nCoV-A quick
overview and comparison with other emerging viruses. Microbes Infect 22,
69–71.
3 Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S,
Rizzardini G, Antinori S & Galli M (2020) COVID-19, cytokines and
immunosuppression: what can we learn from severe acute respiratory
syndrome? Clin Exp Rheumatol 38, 337–342.
4 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X
et al. (2020) Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet 395, 497–506.
5. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD,
White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR,
Hershenson MB, Murray S, Martinez FJ, Moore BB. Periostin promotes
fibrosis and predicts progression in patients with idiopathic pulmonary
fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303(12):L1046–1056.
DOI: 10.1152/ajplung.00139.2012 [PubMed: 23043074]
6. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K,
Ohshima K, Shiraishi H, Uchida M, Ono J, Ohta S, Kato S, Izuhara K,
Aizawa H. Periostin, a matrix protein, is a novel biomarker for
idiopathic interstitial pneumonias. Eur Respir J. 2011;
37(5):1119–1127. [pii]. DOI:
10.1183/09031936.0005981009031936.00059810 [PubMed: 21177844]
7. Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H,
Kushima H, Ishii H, Akasaka K, Ono J, Kamei A, Azuma Y, Matsumoto H,
Yamaguchi Y, Aihara M, Johkoh T, Kawaguchi A, Ichiki M, Sagara H, Kadota
JI, Hanaoka M, Hayashi SI, Kohno S, Hoshino T, Izuhara K. The usefulness
of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis.
PLoS One. 2017; 12(3):e0174547.doi: 10.1371/journal.pone.0174547
[PubMed: 28355256]
8. James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, Ohta S,
Ek A, Middelveld R, Dahlen B, Forsberg B, Izuhara K, Dahlen SE. Serum
periostin relates to type-2 inflammation and lung function in asthma:
Data from the large population-based cohort Swedish GA(2)LEN. Allergy.
2017; doi: 10.1111/all.13181
9. Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular
protein in inflammatory and tumor microenvironments. Matrix Biol
2014;37:150–156.
10. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie
AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of
subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13
signals. J Allergy Clin Immunol 2006;118:98–104.
11. Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y,
Yoshida NL, Maeda M, Pandit A, Lordan JL, et al. Analysis of novel
disease-related genes in bronchial asthma. Cytokine 2002;19:287–296.
12. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron
JR, Holweg CT, Kudo A. The role of periostin in tissue remodeling across
health and disease. Cell Mol Life Sci 2014;71:1279–1288.
13. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ.
Origin of cardiac fibroblasts and the role of periostin. Circ Res
2009;105:934–947.
14. Zeng HL, Chen D, Yan J, Yang Q, Han QQ, Li SS, Cheng L. Proteomic
characteristics of bronchoalveolar lavage fluid in critical COVID-19
patients. FEBS J. 2020 Oct 24. doi: 10.1111/febs.15609. Epub ahead of
print. PMID: 33098359.
15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu
X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B.
Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar
28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020
Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in:
Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.
16. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are
associated with poor prognosis in patients with novel coronavirus
pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. doi:
10.1111/jth.14768. Epub 2020 Mar 13. PMID: 32073213; PMCID: PMC7166509.
17. Bermejo-Martin JF, Almansa R, Menéndez R, Mendez R, Kelvin DJ,
Torres A. Lymphopenic community acquired pneumonia as signature of
severe COVID-19 infection. J Infect. 2020 May;80(5):e23-e24. doi:
10.1016/j.jinf.2020.02.029. Epub 2020 Mar 5. PMID: 32145214; PMCID:
PMC7133663.
18. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P,
Zhang Y. Characteristics of Peripheral Lymphocyte Subset Alteration in
COVID-19 Pneumonia. J Infect Dis. 2020 May 11;221(11):1762-1769. doi:
10.1093/infdis/jiaa150. PMID: 32227123; PMCID: PMC7184346.
19. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H.
Lymphopenia predicts disease severity of COVID-19: a descriptive and
predictive study. Signal Transduct Target Ther. 2020 Mar 27;5(1):33.
doi: 10.1038/s41392-020-0148-4. PMID: 32296069; PMCID: PMC7100419.
Table 1. Baseline characteristics of the patients with and
without COVID-19 infection.